Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Promises and Pitfalls of Regenerative Therapies for Androgenetic Alopecia: Platelet-Rich Plasma, Photobiomodulation, Stem Cells, and Exosomes

Gupta AK., Wang T., Welter R., Unger R., Mejia R.

Narrative Review on Hair Loss, Hair Regeneration, published in Med Sci (Basel) (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Med Sci (Basel) (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41562895
PMCID
PMC12821594
DOI
10.3390/medsci14010005
Citations
1

Abstract (original English)

Background Regenerative therapies have emerged in recent years. In particular, their utility in managing androgenetic alopecia-the most prevalent hair loss condition worldwide, affecting up to half of adults-is an active area of research. Navigating this space can be challenging for physicians due to widespread commercialization, lack of high-quality evidence, and an evolving regulatory landscape. Objective To critically review recently published evidence (2020-2025) on platelet-rich plasma, photobiomodulation, stem cells, and exosomes for the treatment of androgenetic alopecia. Methods A scoping review was conducted using PubMed, Embase (Ovid) and the Cochrane Controlled Register of Trials in February and November of 2025. Combination therapies were excluded. Results and conclusions Platelet-rich plasma is the most studied modality, with emerging investigations into newer formulations such as leukocyte-rich and pure platelet-rich plasma. However, recent studies are limited by inconsistent reporting of cellular composition, short follow-up durations, and a lack of comparative data on treatment protocols. The efficacy of photobiomodulation as a monotherapy remains debated, with inconsistent reporting of device parameters. Stem cells and exosomes show promising, though still limited, clinical evidence in inducing hair regrowth. Standardization of these therapies is crucial, with

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Stem CellsHumansAlopeciaStem Cell TransplantationRegenerative MedicinePlatelet-Rich PlasmaExosomesLow-Level Light Therapy

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research